- Home
- TR vs QURE Comparison
TR vs QURE Comparison
Compare TR & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TR | QURE |
|---|---|---|
| Founded | 1896 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.2B |
| IPO Year | 1994 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TR | QURE |
|---|---|---|
| Price | $41.24 | $48.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 122.4K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | 12.30 | ★ 29.67 |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | $99.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.44 | $8.73 |
| 52 Week High | $45.06 | $71.50 |
Technical Indicators
Market Signals| Indicator | TR | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 59.18 |
| Support Level | $40.27 | $39.50 |
| Resistance Level | $42.25 | $50.47 |
| Average True Range (ATR) | 0.84 | 1.93 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 71.86 | 60.60 |
Price Performance
Historical ComparisonAbout TR Tootsie Roll Industries Inc.
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.